KYTX:NASDAQKyverna Therapeutics, Inc. analysis

Kyverna Therapeutics is trading at $7.92, well below its 20‑day SMA of 8.19 and 50‑day SMA of 8.96, indicating short‑term weakness, yet the RSI of 43 suggests the stock is not yet oversold. The MACD histogram turned positive (0.018) and the signal line is bullish, hinting at a possible technical rebound toward the identified resistance around $9.09. A catalyst has emerged: a registrational trial for miv‑cel in stiff‑person syndrome reported a 46% median improvement in the Timed 25‑Foot Walk, propelling after‑hours shares to $12.04 and underscoring a potential breakthrough therapy.
Fundamentally, the company remains pre‑revenue with negative cash flow and a high beta of 2.73, reflecting pronounced market sensitivity. Nonetheless, the analyst consensus rates the stock as a strong buy with a median target of $32, implying an upside of nearly 300% and positioning KYTX as markedly undervalued relative to its future growth prospects.